Treatment and pre-meds Flashcards
Treatment decision
Based on stage, gleason score, life expectancy, and patient preference
Observation
Elderly of frail men with comorbidities likely out-competing prostate cancer
Monitor w/ expectation to deliver palliative therapy for symptoms
Active surveillance
Actively monitor with expectation to intervene if cancer progresses
Men with >10 yrs life expectancy
EBRT
External beam radiation therapy
Brachytherapy
You’re inserting a needle into the prostate that seeds it with radioactive seeds- avoids side effects from ebrt
RP
Radical prostatectomy
Curative therapy for tumors confined to prostate and life expectancy 10+ years
Urinary incontinence, impotence SIGNIFICANTLY reduced w/ robotic surgery
Don’t do open surgery.
ADT
Androgen deprivation therapy
Goal: testosterone <50 ng/ml
ADT: LHRH agonists
Goserelin
Leuprolide
Triptorelin
Equivalent efficacy and toxicity.
Precede with anti-androgen or continue in combo X 7 days to prevent tumor flare.
Acute: gynecomastia, hot flashes, ED, edema, injection site reactions
Long-term: osteoporosis, obesity, insulin resistance, lipid alterations, increased CV events
ADT: LHRH antagonist
Degarelix
Faster at achieving castrate levels (7d vs 28d) compared to LHRH agonist, no tumor flare
Injection site reactions
Anti-androgens
ONLY used in combo with LHRH agonist to reduce tumor flare
Flutamide, bicalutimide, nilutamide
All cause diarrhea
Recurrence
Treat with surgery or radiation if you haven’t done that before. Treat with hormonal therapy.
If you started with hormonal therapy- anti-androgen withdrawal followed by hormonal therapy.
Castration resistant
Testosterone <20 ng/mL and still progressing.
Docetaxel + prednisone
Abiraterone + prednisone, hyperkalemia, HTN, fluid overload, renin suppression; may be used for docetaxel-refractory CRPC too.
Enzalutamide- first line and docetaxel-refractory CRPC.
Sipuleucel-T $$$$$$$$$$
Cabazitaxel + prednisone is second line, febrile neutropenia risk.
Stage I/II
Observation/AS
RP
RT (EBRT or brachytherapy)
Stage III
Observation/AS
RP + adjuvant RT
EBRT +/- ADT
ADT
Stage IV
*ADT
RT in highly selected patients
Chemotherapy
Immunotherapy
Palliative RT/surgery